These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
968 related articles for article (PubMed ID: 23933902)
21. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective. Duran A; Sengupta N; Diamantopoulos A; Forster F; Kwong L; Lees M J Med Econ; 2011; 14(6):824-34. PubMed ID: 22023098 [TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of enoxaparin versus aspirin in the prevention of venous thromboembolism after total hip or knee arthroplasty: an analysis from the CRISTAL cluster-randomized trial. CRISTAL Economic Analysis Study Group Bone Joint J; 2024 Jun; 106-B(6):589-595. PubMed ID: 38821513 [TBL] [Abstract][Full Text] [Related]
23. Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery. Martin MT; Nutescu EA Curr Med Res Opin; 2011 Nov; 27(11):2123-31. PubMed ID: 21942466 [TBL] [Abstract][Full Text] [Related]
24. Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery in Belgium. Annemans L; Minjoulat-Rey MC; De Knock M; Vranckx K; Czarka M; Gabriel S; Haentjens P Acta Clin Belg; 2004; 59(6):346-57. PubMed ID: 15819379 [TBL] [Abstract][Full Text] [Related]
25. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials. Nieto JA; Espada NG; Merino RG; González TC Thromb Res; 2012 Aug; 130(2):183-91. PubMed ID: 22425218 [TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of apixaban for prevention of venous thromboembolic events in patients after gynecologic cancer surgery. Glickman A; Brennecke A; Tayebnejad A; Matsuo K; Guntupalli SR; Sheeder J Gynecol Oncol; 2020 Nov; 159(2):476-482. PubMed ID: 32854972 [TBL] [Abstract][Full Text] [Related]
27. Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis. King DA; Pow RE; Dickison DM; Vale PR Intern Med J; 2016 Sep; 46(9):1030-7. PubMed ID: 27246450 [TBL] [Abstract][Full Text] [Related]
28. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis. Haentjens P; De Groote K; Annemans L Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714 [TBL] [Abstract][Full Text] [Related]
29. Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery. Dranitsaris G; Stumpo C; Smith R; Bartle W Am J Cardiovasc Drugs; 2009; 9(1):45-58. PubMed ID: 19178131 [TBL] [Abstract][Full Text] [Related]
30. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials. Ma G; Zhang R; Wu X; Wang D; Ying K Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496 [TBL] [Abstract][Full Text] [Related]
31. Economic Evaluations of New Oral Anticoagulants for the Prevention of Venous Thromboembolism After Total Hip or Knee Replacement: A Systematic Review. Brockbank J; Wolowacz S Pharmacoeconomics; 2017 May; 35(5):517-535. PubMed ID: 28185212 [TBL] [Abstract][Full Text] [Related]
32. Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism. Deitelzweig SB; Becker R; Lin J; Benner J Thromb Haemost; 2008 Nov; 100(5):810-20. PubMed ID: 18989525 [TBL] [Abstract][Full Text] [Related]
33. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. Goldhaber SZ; Leizorovicz A; Kakkar AK; Haas SK; Merli G; Knabb RM; Weitz JI; N Engl J Med; 2011 Dec; 365(23):2167-77. PubMed ID: 22077144 [TBL] [Abstract][Full Text] [Related]
34. Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery. Duggan ST Am J Cardiovasc Drugs; 2012 Feb; 12(1):57-72. PubMed ID: 22272729 [TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin. Lee S; Anglade MW; Meng J; Hagstrom K; Kluger J; Coleman CI Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):472-9. PubMed ID: 22740012 [TBL] [Abstract][Full Text] [Related]
36. Apixaban versus enoxaparin in elective major orthopedic surgery: a clinical review. Maniscalco P; Caforio M; Imberti D; Porcellini G; Benedetti R Clin Appl Thromb Hemost; 2015 Mar; 21(2):115-9. PubMed ID: 25125051 [TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences. Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT BMC Health Serv Res; 2017 Jan; 17(1):74. PubMed ID: 28114939 [TBL] [Abstract][Full Text] [Related]
39. The cost-effectiveness of oral direct factor Xa inhibitors compared with low-molecular-weight heparin for the prevention of venous thromboembolism prophylaxis in total hip or knee replacement surgery. Mahmoudi M; Sobieraj DM Pharmacotherapy; 2013 Dec; 33(12):1333-40. PubMed ID: 23625693 [TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence. Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT Clin Ther; 2016 Mar; 38(3):478-93.e1-16. PubMed ID: 26922297 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]